SCYNEXIS, Inc.
General ticker "SCYX" information:
- Sector: Health Care
- Industry: Drug Manufacturers - Specialty & Generic
- Capitalization: $36.4M (TTM average)
SCYNEXIS, Inc. does not follow the US Stock Market performance with the rate: -12.7%.
Estimated limits based on current volatility of 3.6%: low 4.49$, high 4.82$
Factors to consider:
- Total employees count: 18 (-35.7%) as of 2025
- Top business risk factors: Limited profitability history, Clinical trial costs, Regulatory and compliance, Market acceptance, Capital shortage
- Price in estimated range
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [2.84$, 7.62$]
- 2026-12-31 to 2027-12-31 estimated range: [2.28$, 6.31$]
Financial Metrics affecting the SCYX estimates:
- Positive: with PPE of -3.6 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Positive: -51.61 < Industry operating profit margin (median), % of -17.91
- Negative: negative Net income
- Positive: Investing cash flow per share per price, % of 80.34 > 2.08
- Positive: Industry inventory ratio change (median), % of -0.31 <= 0
- Negative: negative Industry operating cash flow (median)
Short-term SCYX quotes
Long-term SCYX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $140.14MM | $3.75MM | $20.60MM |
| Operating Expenses | $67.47MM | $40.86MM | $36.67MM |
| Operating Income | $72.67MM | $-37.12MM | $-16.07MM |
| Non-Operating Income | $-5.49MM | $15.98MM | $7.46MM |
| Interest Expense | $3.13MM | $0.83MM | $0.17MM |
| R&D Expense | $30.93MM | $26.41MM | $22.28MM |
| Income(Loss) | $67.18MM | $-21.14MM | $-8.61MM |
| Taxes | $0.14MM | $0.15MM | $0.00MM |
| Net Income(Loss)* | $67.04MM | $-21.29MM | $-8.61MM |
| Stockholders Equity | $72.96MM | $55.08MM | $49.38MM |
| Assets | $128.41MM | $90.64MM | $59.03MM |
| Operating Cash Flow | $60.16MM | $-24.01MM | $-5.28MM |
| Investing Cash Flow | $-34.88MM | $6.15MM | $24.31MM |
| Financing Cash Flow | $-36.72MM | $-0.14MM | $-14.17MM |
| Earnings Per Share** | $11.21 | $-3.51 | $-1.38 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.